- AI Continent
Matchmaking opportunity for Digital Europe AI-related call topics
The new Digital Europe calls are expected to open in January 2027. Now is the time to look for your potential partners and form consortia.
Read moreNews
The results of the evaluation of the EU Award for Gender Equality Champions competition with call deadline 13 October 2022 are as follows:
Number of applications submitted: 40
Number of inadmissible applications: 24
Number of ineligible applications: 0
Winners: 4
For more information on the winners please see the prize website.
For questions, please contact the Research Enquiry Service.
Source: Funding and Tender Portal
myOverview
Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.
Only for stakeholders located in Flanders
The new Digital Europe calls are expected to open in January 2027. Now is the time to look for your potential partners and form consortia.
Read moreThe 2027 work programme opens funding opportunities worth over €1.8 billion for strategic technologies and scaling up companies. The EIC work programme 2027 details the funding in six main schemes: EIC Pathfinder EIC Transition Advanced Innovation Challenges EIC Accelerator The EIC Strategic Technologies for Europe Platform (STEP) Scale Up EIC...
Read moreESA Space Solutions has opened a call for proposals on space-enabled solutions for resilient electricity grids, in collaboration with ENTSO-E. The call supports proof-of-concept studies and pilot projects that address challenges in grid resilience and operational continuity.
Read moreThe Start2Def 2026 selection process opened on 4 November 2026. Belgian startups and small SMEs can submit proof-of-concept ideas for one of two defence-related challenges.
Read moreTestimonial
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.